# Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma

> **NCT04180995** · PHASE2 · UNKNOWN · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 30 (estimated)

## Conditions studied

- Mucosal Melanoma

## Interventions

- **DRUG:** TORIPALIMAB INJECTION(JS001 ) Axitinib tablet (Inlyta®)

## Key facts

- **NCT ID:** NCT04180995
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-06
- **Primary completion:** 2022-07-06
- **Final completion:** 2022-12-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04180995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04180995, "Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04180995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*